Time to disease progression.

Of the 119 patients in the 600-mg dose group, 39 have progressed, and time to disease progression was censored for the remaining 80. Of the 62 patients in the 400-mg dose group, 39 patients have progressed, and time to disease progression was censored for the remaining 23. The difference between dose groups was statistically significant (P = .002, log-rank test).